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tients. Patients receiving midazolam had higher mortal-
ity rates (31.7%) compared to patients on lorazepam
(29.2%). However, these results were not confirmed
when controlling for disease severity and other factors.
Multivariate regression analysis revealed that type of sed-
ative/analgesic drug treatment and whether the hospital
had a care plan were not associated with shorter ICU and
total hospital stays when controlling for patient demo-
graphics and disease severity. In fact, patients admitted to
hospitals with care plans had longer total hospital stays.
More severe patients had shorter total hospital stays,
probably due to higher mortality. Higher mortality was
associated with older patients and higher disease severity.
CONCLUSION: There is much discussion about treat-
ment guidelines and use of care plans to improve quality
of care and reduce hospitalization costs. In this study, the
type of sedation and analgesia treatment in mechanically
ventilated ICU patients and whether the patient had a
care plan did not influence days in ICU or mortality.
Whether following treatment guidelines and care plans
reduces total costs, needs further evaluation.
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OBJECTIVE: The objective of this study was to deter-
mine the frequency and cost of prescription switches for
90-day vs. 30-day outpatient prescriptions dispensed by a
VA pharmacy and to develop a model to determine the
prescription fill policy with the lowest total costs.
METHODS: VA outpatient prescription records for one
year for simvastatin and lovastatin (30 or 90-days) were
analyzed to determine the frequency, quantity and cost of
medication wasted due to medication switches. The
quantity wasted was defined as the difference between
the quantity dispensed and the quantity of drug used be-
fore changing to a new drug or dosage. Differences in dis-
pensing costs for a given time-period were also included.
Sensitivity analyses were conducted for quantity wasted,
drug costs, and dispensing costs. RESULTS: A total of
16,990 prescriptions were analyzed. The quantity and
costs of medication wasted were higher for 90-day pre-
scriptions than for 30-day prescriptions. However, aver-
age costs to the VA pharmacy were $2.45 higher per pre-
scription for the 30-day supply because of additional
dispensing costs for the 30-day fill. The model and sensi-
tivity analyses show that a 90-day supply policy results in
lower total pharmacy costs under several scenarios. Only
in the case of high drug costs was the 30-day policy fa-
vorable to the 90-day policy in terms of total costs.
CONCLUSION: Prescriptions given in a 90-day supply
resulted in lower total costs. The projected cost savings of
having a 90-day versus a 30-day policy would hold true
for prescriptions with similar drug costs and similar rates
of wastage that result from changes that physicians make
to patients’ prescriptions. In addition, the model provides
a flexible framework for pharmacy administrators to as-
sess refill policies in terms of excess or unnecessary cost
for different classes of drugs, given patient and/or physi-
cian behavior.
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OBJECTIVE: To understand how pharmacy spending
varies across the VA Medical Centers in the United States.
Pharmacy costs continue to rise. From 1990 to 1994
pharmacy expenditures were reported to be 6% of the to-
tal Veteran’s Health Association (VHA) budget. In 1995
and 1996 it was 7%. In 1997 it was 8% and in 1998 it
was 9%. Then in 1999 it went to 11%. Future projections
are for a continued increase in budget spending. METH-
ODS: Ratios of yearly Pharmacy to Medical Center ex-
penditures were compared. These ratios were ranked and
compared with geographical location. The years of 1997
and 1998 were studied. RESULTS: The majority of the
highest ratios were located in the Midwest, Soutwest, and
Southern regions of the United States. CONCLUSIONS:
Financial ratios can demonstrate variations in expendi-
tures and identify areas that may require further inquiry.
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BACKGROUND: A new drug is approved for use if its
effectiveness has been demonstrated. Recently decision-
makers in a number of countries have begun to account
for both the effectiveness and cost-effectiveness of new
drugs. However, cost-effectiveness evidence lags behind
the effectiveness data. OBJECTIVE: To explore the time-
liness of delivering cost-effectiveness information about
new drugs with established effectiveness and significant
financial impact. METHODS: New drugs were identi-
fied, based on guidance documents and reports published
by the National Institute for Clinical Excellence of En-
gland and Wales, and the following data were collected:
dates of publication of first effectiveness and cost-effec-
tiveness evidence, methodology of the cost-effectiveness
analysis, funding of the research, etc. RESULTS: Guid-
ance documents for the following new drugs/drug groups
have been published by NICE by the end of 2000: tax-
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anes for ovarian and breast cancer, proton pump inhibi-
tors in the treatment of dyspepsia, glycoprotein IIb/IIIa
inhibitors, methylphenidate for hyperactivity in child-
hood, zanamivir, and rosiglitazone for type II Diabetes
Mellitus. The analysis of the evidence shows that the ef-
fectiveness of these drugs has been demonstrated in the
last 12 years. However, cost-effectiveness evidence has
been published for 70% of the drugs with an average de-
lay of 3 years (range 0–10). The cost-effectiveness of
those, introduced after 1995 (80% of all included drugs/
drug groups), has been demonstrated using models only,
if at all. CONCLUSIONS: Cost-effectiveness evidence is
produced with a lag behind the effectiveness evidence. As
a result, decision-makers are in a position of awaiting
sound evidence while issuing guidance based on current
inconclusive research results. The cost to society is dis-
cussed, and establishing the cost-effectiveness of new
drugs alongside RCTs at an earlier stage of their develop-
ment is suggested.
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BACKGROUND: As more European governments re-
quire economic data to support reimbursement applica-
tions the potential burden of multiple economic evalua-
tions is being seen as a problem by industry. Placing
responsibility for cost-effectiveness assessment at the Eu-
ropean level using standardised methods has been pro-
posed as a solution. OBJECTIVE: To review the feasibil-
ity of a European level cost-effectiveness test for new
drugs, from conceptual, practical and political view-
points. METHODS: The issues are examined first from
the theoretical perspective—does a European level eco-
nomic evaluation have any inherent logic. Secondly, the
practical issues of how such an evaluation might be con-
ducted are examined. Could it be based on a phase III
clinical trial? The political issues relate to who would reg-
ulate the production of such cost-effectiveness data; who
would use the data to assist in what decision(s)? Different
regulatory models are assessed using the analogy of drug
licensing. DISCUSSION: The position generally taken by
economists is that a generalised cost-effectiveness result is
neither possible nor useful. Differences in the price struc-
tures, treatment patterns and provider incentives between
systems make generalisations of cost-effectiveness of
questionable relevance. How fast will European integra-
tion produce a single health market? Moves towards a
single European price for each drug are relevant as in the
willingness of European states to allow the EU to play a
bigger role in health care financing and organisation.
Will countries accept each others’ assessments or will an
EU agency like EMEA be required? CONCLUSIONS:
Long-term political and economic changes may well cre-
ate a true European market in which cost-effectiveness at
the European level will have meaning and relevance.
Meanwhile, individual country health care systems seem
more concerned with short-term budget impact when
making new drugs available. The pharmaceutical indus-
try should not anticipate a reduction in the overall de-
mand for locally targeted economic information.
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BACKGROUND: The three-tier copayment plan is de-
signed to reduce the cost of pharmacy benefits to the in-
surer or payer while maintaining patient choice. Because
the patient pays a larger portion of the cost of middle-
and high-tier drugs, some have argued that this plan de-
sign may adversely impact patient drug utilization for
chronic medications. OBJECTIVE: To determine whether
a three-tier copayment structure adversely affects patient
drug utilization for middle- and upper-tier drugs for dia-
betes and depression. METHODS: We conducted a lon-
gitudinal, retrospective claims database study using claims
data from a national pharmaceutical benefits management
company. Claims for two chronic conditions, depression
and oral diabetes, were examined for patients on three-tier
copayment plans and for patients on an open formulary
plan with the same copayment for every drug. Average
rates of patient adherence, number of prescriptions filled,
and days of therapy were calculated. RESULTS: There
were statistically significant differences in rates of patient
adherence, number of prescriptions filled, days of therapy,
amount of copay, and payer costs among patients using
drugs in the lower, middle, or upper tier of the three-tier
structure. In addition, average patient adherence, number
of prescriptions filled, and days of therapy did differ signif-
icantly for patients on an open formulary compared to pa-
tients on a three-tier copayment structure. These differ-
ences were largely a function of sample size, and may be of
little practical utility.CONCLUSIONS: The larger patient
copayment for medications in the middle and upper tiers
of a three-tier copayment structure have only a minimal
impact on drug utilization in the antidepressant and oral
diabetes drug categories. Further research is needed to de-
termine whether these findings would be replicated when
applied to other therapeutic classes.
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